N@N

ZIOPHARM Announces 2010 Annual Meeting of Stockholders

^{Published on 2010-06-17 05:42:05 - Market Wire}
 

NEW YORK--([ BUSINESS WIRE ])--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that it will hold its Annual Meeting of Stockholders on Wednesday, June 23, 2010 at 10:00 a.m. EST at the Grand Hyatt New York, Executive Board Room #1418. Stockholders of record at the close of business on May 10, 2010 are entitled to vote at the Annual Meeting. Dr. Jonathan Lewis, Chief Executive Officer, will provide an overview of the Company.

The meeting will be webcast live and can be accessed by visiting the Investors section at [ www.ziopharm.com ]. The webcast will be archived for ninety days.

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer drugs. The Company is currently focused on three clinical programs. Palifosfamide (Zymafos^TM or ZIO-201) references a novel composition (tris formulation) that is the functional active metabolite of ifosfamide, a standard of care for treating sarcoma, lymphoma, testicular, and other cancers.Darinaparsin (Zinapar^TM or ZIO-101) is a novel organic arsenic being developed for the treatment of various hematologic and solid cancers. Indibulin (Zybulin^TM or ZIO-301) is a novel, oral tubulin binding agent that targets both mitosis and cancer cell migration.

ZIOPHARMa™s operations are located in Boston, MA with an executive office in New York City.Further information about ZIOPHARM may be found at [ www.ziopharm.com ].

ZIOP-G

Forward-Looking Safe Harbor Statement:

This press release contains, and statements to be made on behalf of the ZIOPHARM Oncology, Inc. at the Annual Meeting will contain, forward-looking statements regarding the Company. These statements are and will be based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized, that the Company will be able to obtain regulatory approval of its product candidates, that the results of clinical trials will support the Company's claims, that pre-clinical or clinical trials will proceed on schedules that are consistent with the Companya™s expectations or at all, that the Company will be able to protect its intellectual property or rely on third parties to develop its product candidates, that existing capital reserves will be sufficient to fund continued operations for a particular amount of time or that the Company will be able to obtain additional financing to support its operations thereafter. The Company assumes no obligation to update these forward-looking statements, except as required by law.